Science News Roundup: J&J's Stelara succeeds in chronic bowel disease study

Following is a summary of current science news briefs.

J&J's Stelara succeeds in chronic bowel disease study

Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial. Two doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn's disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.